Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, enzalutamide, first line, outcome, PSA | 2 Comments »
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, galeterone, TOK-001, trial | Leave a Comment »
A new paper recently published on line in Urology (“the Gold Journal”) suggests that men with diabetes who are treated with curative intent for localized prostate cancer using external beam radiation therapy may experience higher than normal risk for late genitourinary complications and adverse effects. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: diabetes, external beam, localized, radiation | Leave a Comment »
Last September we asked whether the Oncotype DX test for risk of prostate cancer developed by Genomic Health was “ready for prime time”. In a media release issued earlier this week, the company said that it was. However, there are a number of unresolved issues that are likely to impact the uptake of this new test. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: DX, Oncotype, risk, significant | 3 Comments »
So the American Urology Association (AUA) is clearly “on a roll” when it comes to guidance on the detection and management of prostate cancer. This is the third new guidance document issued in a matter of days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, guideline, radiation therapy, radical prostatectomy, salvage | 4 Comments »
The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, deprivation, response, sub-optimal | Leave a Comment »
According to an article just published on line in Prostate, taking statins before a diagnosis of prostate cancer lowers risk for prostate cancer-specific mortality (but does not lower risk for progression/recurrence of prostate cancer after first-line treatment). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, mortality, risk, statin | 2 Comments »
A podium presentation by Kingman et al. at the upcoming annual meeting of the American Urological Association (AUA) may be among the most significant to be presented at the meeting. It seriously challenges the long-held belief about the need to routinely re-biopsy men initially diagnosed with high-grade prostatic intraepithelial neoplasia (HG-PIN). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, HG-PIN, high-grade, neoplasia, PSA, risk | Leave a Comment »
A paper to be presented at the upcoming AUA annual meeting from what appears to be an ex-US group of clinicians continues to demonstrate the fact that many men get surgical treatment for prostate cancer without anything like a full appreciation of the clinical problem, their treatment options, or the potential consequences. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: decision-making, experience, outcome, radical prostatectomy, satisfaction, surgery | 5 Comments »
Another paper to be presented at the upcoming annual meeting of the American Urological Association (AUA) offers us some additional data on the effectiveness and safety of high-intensity focused ultrasound (HIFU) carried out using the Ablatherm technology and recorded in the @-Registry database. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: Ablatherm, focused, HIFU, high-intensity, outcome, ultrasound | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site